Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 20/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5945997 | 1.00 | CTSS (0.50) | CTSSCYP3A4CYP2C9 | |
| SCHEMBL5946225 | 0.90 | CTSS (0.52) | CTSSCYP3A4CYP2C9 | |
| SCHEMBL14507966 | 0.90 | CTSS (0.49) | CTSSCYP3A4CYP2C9 | |
| SCHEMBL5946218 | 0.90 | CTSS (0.52) | CTSSCYP3A4CYP2C9 | |
| SCHEMBL14507965 | 0.89 | CTSS (0.48) | CTSSCYP3A4CYP2C9 | |
| SCHEMBL5472120 | 0.88 | CTSS (0.51) | CTSSCYP3A4CYP2C9 | |
| SCHEMBL5472122 | 0.88 | CTSS (0.51) | CTSSCYP3A4CYP2C9 | |
| SCHEMBL8285374 | 0.88 | CTSS (0.51) | CTSSCYP3A4CYP2C9 | |
| SCHEMBL5472117 | 0.88 | CTSS (0.51) | CTSSCYP3A4CYP2C9 | |
| SCHEMBL14507978 | 0.86 | CTSS (0.54) | CTSSCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101880-B2 | Peptidic compounds as cysteine protease inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-09-05 | — | — | US | disclosed |
| US-20040127426-A1 | Peptidic compounds as cysteine protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127426-A1 | Peptidic compounds as cysteine protease inhibitors | CTSF, CTSB, CTSS | CTSS 3/4885CYP3A4 3067/4885CYP2C9 3015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.